Health Innovation


The Role of Social Drivers of Health in Clinical Trial Diversity

By Jen Lamppa PhD – Clinical trials have a diversity problem. Despite years of effort, the participants in many studies still fail to reflect the true demographics of the populations they aim to serve. The consequences are profound: limited applicability of results, missed insights, and health inequities that persist across generations.


Four Steps to Tackle Legacy Data Clean Up

By Laurie Seall – Data that sits in a legacy system is at risk of becoming inaccessible. As applications and servers age, they become more vulnerable to cyberattacks and downtime. As the need for data agility and efficiency continues to evolve, it is important to do some cleanup work that will pay off for years to come.


The Role of Predictive Analytics in Preventive Medicine

By Ainsley Lawrence – In our data-centric world, predictive analytics has emerged as a groundbreaking technology, providing powerful insights that can be used to revolutionize preventive medicine. With the proportion of people aged 65 and older increasing at a fast rate and with nearly…



Exploring Grants for Advancing EHR Adoption

By Devin Partida – Healthcare is constantly evolving, which means the demand for more advanced and efficient EHR systems grows stronger. Implementing these systems can be costly, but grants offer a valuable solution to alleviate financial barriers.


Controlling Care Costs for Chronic Kidney Disease

By Julie Schulz MD MPH – In addition to being one of the top 10 causes of death in the United States, chronic kidney disease is a significant driver of cost for commercial insurance and Medicare. However, significant costs can be avoided with earlier detection, better quality care, and aligned physician incentives.


A Sea-Change is Coming in How Laboratory-Developed Tests are Regulated – Is your Lab Ready?

By Inga Rose & and Aaron Schlum – On May 6, FDA published a final rule that will change the way laboratory-developed tests are regulated. The rule phases out the agency’s general policy of “enforcement discretion” and mandates that, across five stages within the next four years, LDTs will be beholden to the same regulatory requirements as in vitro diagnostics.